---
schema_version: "secwatch.filing_event.v1"
accession: "0001725160-25-000104"
form_type: "8-K"
ticker: "ZNTL"
cik: "0001725160"
company_name: "Zentalis Pharmaceuticals, Inc."
filed_at: "2025-05-14T23:59:59+00:00"
generated_at: "2026-05-21T09:09:37.609400+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Zentalis Q1 2025 cash $332.5M; first patient dosed in DENALI Part 2 azenosertib trial

## Summary
- Cash $332.5M (incl. $12.2M Immunome stock) at March 31, 2025; runway into late 2027.
- First patient dosed in DENALI Part 2a for azenosertib in Cyclin E1+ platinum-resistant ovarian cancer.
- Topline data from DENALI Part 2 expected by year-end 2026; potential for accelerated approval.
- R&D expenses $27.2M vs $49.6M YoY; total operating expenses $45.6M including $7.8M restructuring.
- Prior Part 1b data: ORR 34.9%, median DOR 6.3 months in evaluable Cyclin E1+ PROC patients.

## SEC filing metadata
- accession: 0001725160-25-000104
- form_type: 8-K
- ticker: ZNTL
- cik: 0001725160
- company_name: Zentalis Pharmaceuticals, Inc.
- filed_at: 2025-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1725160/000172516025000104/0001725160-25-000104-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1725160/000172516025000104/zntl-20250514.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001725160-25-000104
- JSON: https://secwatch.observer/filing/0001725160-25-000104.json
- Plain text: https://secwatch.observer/filing/0001725160-25-000104.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.